Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Gains from Sales and Divestitures (2017)

Cytokinetics (CYTK) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $171250.0 as the latest value for Q4 2017.

  • Quarterly Gains from Sales and Divestitures changed N/A to $171250.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $171250.0 through Dec 2017, changed N/A year-over-year, with the annual reading at $171250.0 for FY2017, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2017 was $171250.0 at Cytokinetics, up from $42078.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $211897.0 in Q3 2013, with the low at $42078.0 in Q4 2015.
  • Average Gains from Sales and Divestitures over 3 years is $159280.5, with a median of $191573.5 recorded in 2013.
  • Peak annual rise in Gains from Sales and Divestitures hit 115.23% in 2013, while the deepest fall reached 8.64% in 2013.
  • Over 3 years, Gains from Sales and Divestitures stood at $211897.0 in 2013, then plummeted by 80.14% to $42078.0 in 2015, then soared by 306.98% to $171250.0 in 2017.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $171250.0, $42078.0, and $211897.0 for Q4 2017, Q4 2015, and Q4 2013 respectively.